SLC5A2 and type 2 diabetes mellitus: This study demonstrated no discernible increase in the risk of UTI development associated with the use of SGLT2 inhibitors in patients with T2DM, compared with the reported rates of UTIs, thus supporting the safety profile of SGLT2 inhibitors.